treatment with DIELEN Protect

Phase 3Small molecule

treatment with DIELEN Protect is one of 69 small molecule programs targeting Colorectal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CancerActive, not recruiting

Irritable Bowel SyndromeActive, not recruiting

Colorectal CancerPhase 3

Active, not recruiting

Irritable Bowel SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

949 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

treatment with DIELEN Protect

UUniversity Hospital, Rouen

Phase 3

1 2

Eylea

Regeneron

Preclinical

5 3

Emend IV

PORTRAZZA

Gas-X

PPortuguese Oncology Institute, Coimbra

Preclinical

1 6

Ketalar

AAultman Health Foundation

Preclinical

1 7

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 8

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Bridion

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 10

Andriol

AAuxilium

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Irritable Bowel Syndrome

NCT07039747

Q2 2032

Phase 3Not yet recruiting

Colorectal Cancer

NCT06446557

Clinical

Trials by Indication[1]

Colorectal Cancer1 trial

De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer

Not yet recruiting·UUniversity Hospital, Rouen·Phase 3·NCT06446557·408 enrolled

Irritable Bowel Syndrome1 trial

Effectiveness of a Dietary Supplement in Irritable Bowel Syndrome

Recruiting·UUniversity Hospital, Rouen·Phase 2·NCT07039747·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for treatment with DIELEN Protect. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — treatment with DIELEN Protect compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for treatment with DIELEN Protect. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Rouen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity Hospital, Rouen

treatment with DIELEN Protect

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2032

Trials by Indication[1]

Colorectal Cancer1 trial

Irritable Bowel Syndrome1 trial

References

Drug Info

Quick Facts

Related News